LPA and coronary artery disorder: It aims to evaluate the reduction in Lp(a) by baseline Lp(a) levels and numbers of KIV domains, to estimate by how much Lp(a) reduction with niacin–laropiprant might be expected to reduce coronary heart disease risk.